Ella Instrument- Automated Immunoassay Machine acquisition

The contract pertains to the acquisition of the Ella Immunoassay System, an automated instrument designed for high-throughput, multiplexed protein analysis in serum and plasma samples. This system is critical for the Translational Neuroradiology Section of the National Institute of Neurological Disorders and Stroke, under the NIH, to facilitate advanced research into multiple sclerosis and related neuroinflammatory diseases. The Ella platform is valued for its high sensitivity, minimal sample volume requirements, rapid results, and consistent reproducibility, particularly in quantifying key biomarkers like neurofilament light chain and glial fibrillary acidic protein, which are essential for monitoring CNS damage and astrocyte activity. Issued as a presolicitation by the Department of Health and Human Services with a response deadline in early June 2026, this contract will support ongoing efforts to enhance immune profiling and biomarker studies critical to understanding the mechanistic underpinnings of neurodegenerative diseases. The acquisition aims to maintain the rigor and precision necessary for high-impact translational neuroimmunology research, with the place of performance in Bethesda, Maryland. The solicitation is open without any set-aside restrictions, and further details or communications can be directed to the primary contact at the NIH provided in the announcement.